851008-45-2

Upstream product

• 851008-48-5 1-(cyclopropylsulphanyl)-4-nitrobenzene 
• 354-38-1 2,2,2-trifluoroacetamide 
• 420-04-2 CYANAMID 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 1223498-43-8 (R,S)-S-cyclopropyl-S-(4-nitrophenyl)-N-(trifluoroacetyl)sulfoximide 
• 1223498-26-7 (R,S)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide 
• 1223498-44-9 (R,S)-S-(4-aminophenyl)-S-cyclopropyl-N-(trifluoroacetyl)sulfoximide 
• 1223498-51-8 (R,S)-S-(4-{[4-{[(1R,2R)-2-(benzyloxy)-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-S-cyclopropyl-N-(trifluoroacetyl)sulfoximide 
• 1223498-94-9 (R,S)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-N-(trifluoroacetyl)sulfoximide 
• 1223498-31-4 (RS)-S-cyclopropyl-S-(4-{[4-{[(R)-2-hydroxy-1,2-dimethylpropyl]amino}-5-(trifluoromethyl)-pyrimidin-2-yl]amino}phenyl)sulfoximide 
• 1223498-42-7 (R,S)-S-{4-[(5-bromo-4-{[(2R,3R)-2-hydroxy-1-methylpropyl]oxy}pyrimidin-2-yl)amino]phenyl}-S-cyclopropylsulfoximide 
• 1223498-65-4 (R,S)-S-{4-[(5-bromo-4-{[(2R,3R)-2-hydroxy-1-methylpropyl]oxy}-pyrimidin-2-yl)amino]phenyl}-S-cyclopropyl-N-(trifluoroacetyl)sulfoximide 
• 1223498-76-7 C₁₉H₂₄F₃N₅O₂S 
• 1223498-74-5 C₁₉H₂₄F₃N₅O₂S 
• 1223498-89-2 C₁₈H₂₂F₃N₅O₂S 
• 1223498-91-6 C₁₈H₂₂F₃N₅O₂S 
• 1223498-67-6 (S)-S-cyclopropyl-S-(4-{[4-{[(1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide 
• 1223498-69-8 (R)-S-cyclopropyl-S-(4-{[4-{[(1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide 

Relevant academic research and scientific papers

A practical approach to N-(trifluoroacetyl)sulfilimines

A new, simple method for the synthesis of N-(trifluoroacetyl)-protected sulfilimines from sulfides by a transition-metal-free, one-pot protocol is presented. The salient features of this process include the use of low-cost 1,3-dibromo-5,5-dimethylhydantoin, mild reaction conditions, and a broad substrate scope. The safety and robustness of the method has also been demonstrated by operations on a kilogram scale. In addition, a chiral resolution of a corresponding sulfoximine was achieved on a large scale. Georg Thieme Verlag Stuttgart. New York.

The lab oddity prevails: Discovery of Pan-CDK inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY1000394) for the treatment of cancer

Lead optimization of a high-throughput screening hit led to the rapid identification of aminopyrimidine ZK304709, a multitargeted CDK and VEGF-R inhibitor that displayed a promising preclinical profile. Nevertheless, ZK304709 failed in phaseI studies due

SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE

The invention relates to sulfoximine-substituted anilino-pyrimidine derivatives of formula (I). methods of production thereof, and use thereof as medication for the treatment of various diseases.